JPMorgan analyst Richard Vosser upgraded Novartis to Neutral from Underweight with a price target of CHF 85, up from CHF 78. The analyst continues to see a "bifurcation" in European pharma company outlooks in 2023, both in terms of pipeline readouts and longer-term where "genericisations again need to be navigated." As such, he would avoid companies like GSK and Roche, seeing downside to 2023 consensus estimates and "potentially challenged" 2025-2030 outlooks. Vosser continues to favor companies "which have sustainably higher growth" and "far more" pipeline data points, new launches to drive estimate upgrades.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis (NYSE:NVS) Could Loose $245M in Litigation Settlement
- Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports
- Sandoz Canada supports Ontario policy change on biosimilars
- Novartis call volume above normal and directionally bullish
- Harrow Health signs binding agreement to acquire rights to ophthalmic products
